After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares ... David and Tom Gardner have a stock tip, it can …
La Jolla Pharmaceutical Company (NASDAQ: LJPC) announced that it has called a ... available for distribution to holders of the approximately 66M shares of common stock issued and outstanding.
ETRM closed Monday's trading at $1.94, up 1.57%. In after-hours, the stock gained another 7.73% to $2.09. La Jolla Pharmaceutical Co.'s (LJPC) New Drug Application for LJPC-501 for the treatment of hypotension in adults with …
Investors in La Jolla Pharmaceutical Company LJPC need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 16th, 2017 $20 Put had some of the highest implied volatility of all equity …
Equities under review are: Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC), Cytori Therapeutics Inc. (NASDAQ: …
NBC 24mon
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LJPC at https://www.zacks.com/ap/LJPC Keywords: La Jolla …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
With analysts calling for LJPC-501 to potentially deliver peak sales in excess ... than La Jolla Pharmaceutical When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run …